GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02564692 |
|
Recruitment Status :
Recruiting
First Posted : October 1, 2015
Last Update Posted : June 8, 2021
|
Sponsor:
Banner Health
Information provided by (Responsible Party):
Jessica Langbaum, PhD, Banner Health
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the Alzheimer's Prevention Registry GeneMatch program is to identify a large group of people interested in participating in research studies or clinical trials based in part on their genetic background. This genetic information will be used to match interested individuals to studies, providing a recruitment resource to the Alzheimer's scientific community. Interested individuals should visit www.endALZnow.org/GeneMatch to join the GeneMatch program.
| Condition or disease |
|---|
| Alzheimer Disease |
The primary objectives of the Alzheimer's Prevention Registry GeneMatch program are to (1) identify and characterize a large cohort of people who are interested in, and may be eligible to participate in, current and future preclinical Alzheimer's disease research studies and clinical trials based on their genetic background, and (2) provide information to these individuals about research studies for which they may be eligible, based in part on their genetic background. Cognitively unimpaired individuals age 50 to 90, inclusive, are eligible to enroll in GeneMatch. GeneMatch will provide participants with a genetic sample kit (a cheek swab) to test for a specific gene called apolipoproteins E (APOE). GeneMatch does not disclose the results of the APOE test to participants. GeneMatch may use the APOE test results to match participants to research studies. Participants are under no obligation to pursue these study opportunities.
| Study Type : | Observational [Patient Registry] |
| Estimated Enrollment : | 500000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Target Follow-Up Duration: | 15 Years |
| Official Title: | Alzheimer's Prevention Registry GeneMatch Program |
| Study Start Date : | November 2015 |
| Estimated Primary Completion Date : | December 2030 |
| Estimated Study Completion Date : | December 2030 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Alzheimer disease
Primary Outcome Measures :
- Number of individuals who enroll in GeneMatch [ Time Frame: 15 years ]
Secondary Outcome Measures :
- Number of individuals referred to research studies [ Time Frame: 15 years ]
- Number of individuals who enroll in research studies [ Time Frame: 15 years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years to 90 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
This large research study will ultimately enroll 500,000 adults. We will recruit subjects from all over the United States, as everything is done via email, mail, or/and phone.
Criteria
Inclusion Criteria:
- Age 50-90, inclusive
- Provide basic demographic, medical history, and contact information
- Consent to APOE genotyping without receiving results
- Live in the United States
Exclusion Criteria:
- Unable to comply with this project's protocol requirements
- Self-reported diagnosis of dementia or any other objective cognitive impairment syndrome
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564692
Contacts
| Contact: David Gordon, MS | 1-888-STOP-ALZ | GeneMatch@endALZnow.org |
Locations
| United States, Arizona | |
| Banner Alzheimer's Institute | Recruiting |
| Phoenix, Arizona, United States, 85006 | |
| Contact: David Gordon GeneMatch@endalznow.org | |
| Principal Investigator: Jessica B Langbaum, PhD | |
Sponsors and Collaborators
Banner Health
Investigators
| Principal Investigator: | Jessica B Langbaum, PhD | Banner Alzheimer's Institute |
Additional Information:
Publications of Results:
Publications of Results:
| Responsible Party: | Jessica Langbaum, PhD, Director, Alzheimer's Prevention Initiative, Banner Health |
| ClinicalTrials.gov Identifier: | NCT02564692 |
| Other Study ID Numbers: |
APR-001 |
| First Posted: | October 1, 2015 Key Record Dates |
| Last Update Posted: | June 8, 2021 |
| Last Verified: | June 2021 |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |